

COVER SHEET FOR RESPONSES

Contact details of respondent	
Name	
Job Title (if applicable)	
Organisation (if applicable)	
Postal address	
Telephone number	
Email address	

Please indicate below which issues are covered by your response. Not all issues will be relevant to all respondents – please feel free to skip questions that are not relevant to you.

General Questions covered:	
How IP is awarded	
How IP is used	
How IP is licensed and exchanged	
How IP is challenged and enforced	

Specific Issues covered:	
Current term of protection on sound recordings and performers' rights	
Copyright exceptions – fair use and fair dealing	
Copyright – digital rights management	
Copyright – orphan works	
Copyright – licensing of public performances	
Copyright – designated archive status	
Patents – utility patents	
Pharmaceutical Supplementary Protection Certificates (SPCs)	
Trade Marks – international issues	
Designs – registered designs and unregistered design rights	
Legal sanctions on IP infringement	
Parallel Imports / International Exhaustion	
Coherence between competition policy and IP policy	

Have you raised any other issues in your response?

Y / N

Details of accompanying documents (Please continue on additional sheet if necessary)

Please **TICK BOX** if you **DO NOT** want your response posted on the **Gowers Review website.**

GOWERS REVIEW OF INTELLECTUAL PROPERTY
Zone 4/E1
HM Treasury
1, Horse Guards Road
LONDON SW1A 2HQ

Our ref.: IPD/0604-079

April 28, 2006

Your ref.:

Re: Gowers Review of Intellectual Property – Call for evidence.

Dear Sirs,

This submission is being made by UCB S.A. *via* its UK Branch UCB Celltech. UCB's presence in the UK is primarily comprised of R&D Centres of Excellence in Slough and Cambridge gained in the acquisition of the premier UK biotech company Celltech in 2004.

UCB (www.ucb-group.com) is a global biopharmaceutical leader, specialized in severe diseases within the fields of central nervous system disorders (including epilepsy), allergy/respiratory diseases, immune and inflammatory disorders and oncology. Employing 8,500 people in 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on Euronext Brussels.

As a biopharmaceutical company UCB is heavily reliant on patents and other forms of IP to protect the fruits of its very heavy investment in innovative R&D (> 20% of net sales).

This is particularly so for a company such as ours, where our size requires us to focus on a manageable number of key products.

In terms of IP, we agree with and fully endorse the positions put forward by the ABPI in their submission.

With respect to SPC's, our key products in the UK are largely protected by SPC's and we, therefore, welcome the suggestions:

Celltech antibody centre of excellence
UCB Celltech - The UK Branch of UCB S.A.
A Limited Liability Company Incorporated in Belgium
Representative Office: 208 Bath Road, Slough, Berkshire SL1 3WE
Main Tel: (0)1753 534655
Main Fax:(0)1753 536632
Branch Registration No. BR007969


- a) to allow a compensatory period equal to the full delay between grant of patents and issuance of market authorisation; and
- b) to allow multiple SPC's for innovative drug products comprising the same drug substance.

Our return on R&D investment is also significantly impacted by parallel imports and we can only confirm the general observations of ABPI that such trading, even when within the bounds of that which is rightly permitted, shows scant evidence of benefiting either patient or purchaser which should surely be its goal. In the vast majority of cases the potential savings flow entirely to the parallel trader who have made no contribution whatsoever to the discovery and development of the product.

We welcome this opportunity to comment and request and look forward future involvement in this evaluation process as its moves forward.

Yours faithfully,



 Allen Norris
Vice President
Head of Group IP